About Us

Eolas Longevity’s lead drug candidate is a well-characterised small molecule designed to slow the formation of, and selectively clear senescent cells. Lab studies have shown a significant rejuvenation of older cells. The drug has already been approved outside the US and Europe for another disease. Existing data will significantly reduce development risk and shorten the timeline to approval in the US and Europe.

Our Approach

Eolas uses a proprietary clinical proxy model, in a specific patient

population, that mirrors natural human aging at an accelerated rate. This model, combined with the drug compound’s existing safety data, allows us to observe human efficacy in a fraction of the time required for traditional aging studies.

Team

Iain Forbes

Chief Executive Officer

A geneticist and pharmacologist with over 30 years’ experience as a CEO, Scientific director. and in clinical trial management. Iain collaborated with Boots PLC in developing products based on anti-senescence technology

Dr Alan Walker

Chair

Alan has over 50 years’ experience in pharma and biotech. He was country and regional CEO at a US multinational pharma before its sale to Pfizer. Alan was directly responsible for the first launches of Neurotin (Gabapentin), and Lipitor (Atorvastatin), which became the world’s most valuable medicine. Alan has more recently had a biotech career in Scotland. Highlights included a successful exit of Internis delivering a 30x investor return.

Matthew Alsop

Chief Financial Officer

Matthew is a Commercial and Finance Director with more than 25 years of international experience focused on the Pharmaceutical and Engineering industries. Matthew has a breadth of knowledge in effective financial management and also brings experience in fund raising and in the management of successful exits. He played an important role in the financial exits of two SMEs in the Pharmaceuticals and Engineering sectors.

Professor Paul Shiels

Chief Executive Officer

Paul is a recognised expert in cell senescence and aging genetics. His career has spanned industry and academia and he spent 25 years developing an understanding of biological ageing. He was among the first globally to clone and analyse telomeres. At PPL Therapeutics, Roslin, he helped develop the internationally recognised Xenotransplantation programme and undertook the analysis of senescence in Dolly the sheep.

Dr. William Forbes

Clinical Advisor & Board Member

Clinician of considerable standing and experience, with a career in heart surgery, cardiology and degrees in medicine, cardiology and physiology. Bill, contributed to the company’s intellectual property. Career highlights include his developed of the world’s leading salt substitute ‘Lo-Salt’ for Klinge Chemicals in the 1980’s and the development of pace-maker technology in the 1960’s.

Professor Alex Mullen

Formulation Expert Adviser

Alex is a registered pharmacist and previously worked in the pharmaceutical industry with Reckitt Benckiser and on a WHO-financed project involving the development of parenteral liposomal delivery systems for infectious diseases. Alex has an extensive research portfolio, encompassing oral and vesicular drug delivery technologies, drug eluting stents, liposomes, vaginal and vaccine delivery systems.